Acceleration of Schwann cells proliferation in vitro using FK506

被引:0
|
作者
Cheng, Biao [1 ]
Chen, Zhen-rong [1 ]
Lin, Jian-ping [1 ]
机构
[1] Department of Orthopedics, Zhanshan Hospital, Fudan University, Shanghai 200032, China
来源
关键词
Growth kinetics - Immunology - Microscopic examination - Neurology;
D O I
暂无
中图分类号
学科分类号
摘要
Purpose: To explore the role and mechanism of FK506 in promoting peripheral nerve regeneration. Methods: The purified Schwann cells from rabbits were divided into three group: 10 μg/L FK506 and the control group. Following 10 days in vitro, the cells from three groups were counted with phase contrast microscope every day to draw proliferation curve respectively. Flow cytometries were carried out in each group after 24 and 72 h respectively. Results: The Schwann cells grew well and a lot of balloons in the shruken fibroblasts cytoplasm were discovered in FK506 groups. The doubling time of control group was 8 days, the 10 and 100 μg/L FK506 group were 6.2 days respectively. The flow cytometry of the three groups showed that Schwann cells in S phase of the two FK506 groups were significanly higher than the control group(P < 0.01). Conclusions: FK506 could promote Schwann cell proliferation and restain the growth of fibroblast in vitro. The double role of immunosuppressive agent FK506 may have broad application prospect in treatment of nerve regeneration.
引用
收藏
页码:208 / 210
相关论文
共 50 条
  • [31] CSA AND FK506 REGULATION OF CYTOKINES
    NGUYEN, D
    DEFORGE, L
    REMICK, D
    FASEB JOURNAL, 1991, 5 (06): : A1638 - A1638
  • [32] TAUTOMERIC PHENOMENON OF FK506 IN SOLUTION
    NAMIKI, Y
    KIHARA, N
    FUJIOKA, M
    SHIMATANI, K
    FUJIWARA, A
    HANE, K
    YASUDA, T
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1992, 203 : 72 - ANYL
  • [33] Interaction of FK506 with antizyme inhibitor
    Mangold, U
    Musicki, B
    Ohage, S
    Wendler, W
    Kirschbaum, B
    Leberer, E
    MOLECULAR BIOLOGY OF THE CELL, 2000, 11 : 242A - 242A
  • [34] FK506与心脏移植
    孟旭
    陈宝田
    中华胸心血管外科杂志, 1998, (02) : 58 - 60
  • [35] Behavioral assessment of neuroprotection by FK506
    Marston, HM
    Sharkey, J
    IMMUNOPHILINS IN THE BRAIN: FKBP LIGANDS: NOVEL STRATEGIES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, 2000, : 173 - 182
  • [36] ORAL ABSORPTION OF FK506 IN RATS
    KAGAYAMA, A
    TANIMOTO, S
    FUJISAKI, J
    KAIBARA, A
    OHARA, K
    IWASAKI, K
    HIRANO, Y
    HATA, T
    PHARMACEUTICAL RESEARCH, 1993, 10 (10) : 1446 - 1450
  • [37] The mechanism of action of cyclosporin A and FK506
    Ho, S
    Clipstone, N
    Timmermann, L
    Northrop, J
    Graef, I
    Fiorentino, D
    Nourse, J
    Crabtree, GR
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 80 (03): : S40 - S45
  • [38] Stability of FK506 in blood samples
    Alak, AM
    Lizak, P
    THERAPEUTIC DRUG MONITORING, 1996, 18 (02) : 209 - 211
  • [39] FK506研究进展
    唐功耀
    鲍镇美
    临床泌尿外科杂志, 1993, (02) : 118 - 121
  • [40] Comparison of FK506 and cyclosporine - Reply
    Gjertson, DW
    Cecka, JM
    TRANSPLANTATION, 1996, 62 (05) : 702 - 702